Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genta launches Genasense named patient/compassionate use program
Named patient distribution refers to the distribution or sale of a product to a specific healthcare professional for the treatment of an individual patient. In most countries, this
Named patient distribution refers to the distribution or sale of a product to a specific healthcare professional for the treatment of an individual patient. In most countries, this
According to the company, Kuvan, an investigational oral small molecule, resulted in significant reductions in blood Phe levels in some phenylketonuria (PKU) patients. The Phase III clinical study
BioMarin established a marketing and distribution agreement with AnGes in December 2006, through which AnGes obtained exclusive rights to market Naglazyme in the Japanese market. Naglazyme was approved
This fenofibrate uses LifeCycle Pharma’s Meltdose technology, which is designed to provide enhanced absorption and greater bioavailability. Under the terms of the agreement with Sciele, LifeCycle Pharma has
These rights were acquired from Queen Mary, University of London. The conditions targeted by the inventions include osteoarthritis, rheumatoid arthritis, inflammatory bowel disease, and cardiac reperfusion (restoration of
Abraxis Pharmaceutical Products (APP) claims that cefotetan has the longest half-life of any first- or second-generation cephalosporin and offers surgeons a convenient single-dose option for surgical prophylaxis and
The verapamil capsules are the generic version of Elan Drug Delivery’s Verelan tablets for the treatment of high blood pressure. Verapamil capsules had US sales of approximately $58
Although high blood pressure is more prevalent in adults, Novartis says that it has been reported that nearly 5% of children and adolescents in the US may have
Zabofloxacin is a fluoroquinolone antibiotic with enhanced in-vitro activity against Streptococcus pneumoniae, including strains resistant to other antibiotics. The spectrum of activity of Zabofloxacin includes those bacterial strains
Established in 1999, the National Institute for Health and Clinical Excellence reviews newly approved drugs and decides whether they will be available on the NHS based on their